EP
RMD icon

Eudaimonia Partners’s ResMed RMD Stock Holding History

Eudaimonia Partners’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-103
Closed -$20K – 1149
2021
Q1 		$20K Sell
103
-20
-16% -$4.01K ﹤0.01% 944
2020
Q4 		$26K Sell
123
-7
-5% -$1.4K 0.01% 794
2020
Q3 		$22K Hold
130
– – 0.01% 776
2020
Q2 		$25K Buy
+130
New +$21.3K 0.01% 672

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Eudaimonia Partners's RMD Position: Q2 2021 in Review

Eudaimonia Partners sold out of ResMed (RMD) in Q2 2021, closing a stake of 103 shares — an estimated $20K sold.

Eudaimonia Partners first reported a position in RMD in Q2 2020 and held it in 4 quarters. The position peaked at $26K in Q4 2020. 661 funds tracked by Wall St. Rank hold RMD as of Q2 2021.

  • Eudaimonia Partners reported no remaining ResMed position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 103 ResMed shares in Q2 2021, an estimated $20K.
  • Eudaimonia Partners first reported a position in ResMed in Q2 2020 and held it in 4 quarters.
  • Eudaimonia Partners's ResMed position peaked at $26K in Q4 2020.
  • 661 funds tracked by Wall St. Rank held ResMed as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.